# US 11,998,520 B2 · Methods for decreasing injuries associated with intraoperative hypotension > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,998,520 B2 - Document ID: US11998520B2 - Status: Granted - Kind: B2 - Application number: 17/466,778 - Filed: 2021-09-03 - Published: 2021-12-30 - Granted: 2024-06-04 - Earliest claimed: 2017-01-08 - Assignees: The United States Government as represented by the Department of Veterans Affairs - Applicants: ResQ Pharma, Inc. - Inventors: Guy Weinberg - Web page: https://patentgrep.com/patent/US11998520B2 ## CPC - A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids - A61K 31/047: having two or more hydroxy groups, e.g. sorbitol - A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids - A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557) - A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin - A61K 38/085: {Angiotensins} - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)} - A61P 9/00: Drugs for disorders of the cardiovascular system - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present disclosures provides methods for decreasing injuries associated with intraoperative hypotension by intravenously administering to a subject a therapeutically effective amount of a fat emulsion, following a period of intraoperative hypotension and after the subject's mean arterial blood pressure has recovered. The disclosure also provides methods for preventing injuries associated with intraoperative hypotension, particularly for surgical candidates that have an increased risk for intraoperative hypotension. Non-limiting examples of injuries contemplated herein include myocardial injury, myocardial infarction, and acute kidney injury. ## Claims ### Claim 1 A method for decreasing myocardial injury or acute kidney injury in a subject following intraoperative hypotension, the method comprising intravenously administering to the subject a therapeutically effective amount of a fat emulsion after the subject's mean arterial pressure (MAP) is recovered to greater than or equal to 66 mm Hg, wherein administration of the therapeutically effective amount of the fat emulsion results in at least a 10% decrease in a marker of myocardial injury or acute kidney injury as compared to a control group that did not receive the fat emulsion, wherein the marker of myocardial injury is cardiac troponin or heart-type fatty acid binding protein, or wherein the marker of acute kidney injury is creatinine or lipocalin-2. ### Claim 2 (depends on 1) The method of claim 1, wherein the cardiac troponin is cardiac troponin C. ### Claim 3 (depends on 1) The method of claim 1, wherein the cardiac troponin is cardiac troponin T. ### Claim 4 (depends on 1) The method of claim 1, wherein the decrease is measured about two hours, twelve hours, twenty-four hours, seven days, fourteen days, thirty days, three months, or six months postoperatively. ### Claim 5 (depends on 4) The method of claim 4, wherein the decrease is at least 20%, at least 30%, or at least 50%. ### Claim 6 (depends on 1) The method of claim 1, wherein the intraoperative hypotension occurred for at least about 30 seconds, at least about one minute, at least about five minutes, or at least about ten minutes. ### Claim 7 (depends on 1) The method of claim 1, wherein the subject's arterial blood flow was reduced but not completely occluded during the period of intraoperative hypotension. ### Claim 8 A method for decreasing postoperative mortality in a subject following intraoperative hypotension, the method comprising intravenously administering to the subject a therapeutically effective amount of a fat emulsion after the subject's mean arterial pressure (MAP) is recovered to greater than or equal to 66 mm Hg, wherein mortality reduced by at least 10% as compared to a control group that did not receive the fat emulsion. ### Claim 9 (depends on 8) The method of claim 8, wherein the subject's arterial blood flow was reduced but not completely occluded during the period of intraoperative hypotension. ### Claim 10 (depends on 9) The method of claim 9, wherein the intraoperative hypotension occurred for at least about 30 seconds, at least about one minute, at least about five minutes, or at least about ten minutes. ### Claim 11 (depends on 9) The method of claim 9, wherein the intraoperative hypotension occurred for at least about 30 seconds, at least about one minute, at least about five minutes, or at least about ten minutes. ### Claim 12 A method for decreasing 30-day or one year mortality following general anesthesia for a subject who has intraoperative hypotension while under general anesthesia, the method comprising intravenously administering to a subject a therapeutically effective amount of a fat emulsion after the subject has received one or more reperfusion therapies to restore mean arterial pressure (MAP) to 66 mm Hg or higher, wherein the subject is not in shock at the time the fat emulsion is administered. ### Claim 13 (depends on 12) The method of claim 12, wherein the decrease is at least 20%, at least 30%, at least 40%, or at least 50%. ### Claim 14 (depends on 12) The method of claim 12, wherein the subject's arterial blood flow was reduced but not completely occluded during the period of intraoperative hypotension. ### Claim 15 (depends on 12) The method of claim 12, wherein the intraoperative hypotension occurred for at least about 30 seconds, at least about one minute, at least about five minutes, or at least about ten minutes.